ArticleAdvances in experimental medicine and biology2022
HDL and Diabetes.
Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- High-density lipoprotein in diabetes: Structural and functional relevance.Journal of diabetes investigation · 2024Review
- ANGPTL3 is a novel HDL component that regulates HDL function.Journal of translational medicine · 2024Article
- New Player in an Old Field? Ecto-FArteriosclerosis, thrombosis, and vascular biology · 2024Article
- Analysis of the Association Between Changes in the GGT/HDL-C Ratio and the Risk of Diabetes Mellitus Based on a Latent Class Growth Mixed Modeling: A Longitudinal Cohort Study of Adults in China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Alanine aminotransferase to high- density lipoprotein cholesterol ratio is positively correlated with the occurrence of diabetes in the Chinese population: a population-based cohort study.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a worldwide public health issue, with the number of cases expected to reach 642 million by 2040. Patients with diabetes are at a two- to four-fold increased risk of developing cardiovascular disease. This chapter focuses on the anti-diabetic and cardioprotective functions of plasma high-density lipoproteins (HDLs). HDLs and the main HDL apolipoprotein, apoA-I, improves pancreatic beta cell function. ApoA-I also improves insulin sensitivity. The development of novel, bifunctional HDL-based interventions are a promising therapeutic option for the treatment of cardiometabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.